Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24274345 | 0.86 | YTHDC1 (0.32) | YTHDC1CYP2C19 | |
| SCHEMBL24294418 | 0.86 | YTHDC1 (0.30) | YTHDC1CYP2C19 | |
| SCHEMBL29474165 | 0.85 | — | — | |
| SCHEMBL28954102 | 0.84 | CYP1A2 (0.31) | — | |
| SCHEMBL24305269 | 0.84 | YTHDC1 (0.31) | YTHDC1CYP2C19 | |
| SCHEMBL29474766 | 0.82 | ATR (0.30) | YTHDC1 | |
| SCHEMBL24274517 | 0.82 | YTHDC1 (0.32) | YTHDC1 | |
| SCHEMBL24274346 | 0.81 | BRAF (0.31) | — | |
| SCHEMBL31178706 | 0.77 | CYP4F2 (0.33) | YTHDC1CYP2C19 | |
| SCHEMBL29474176 | 0.75 | ALDH1A1 (0.41) | GAAYTHDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834467-B2 | Substituted indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors | 1ST Biotherapeutics, Inc. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-11834467-B2 | Substituted indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors | 1ST Biotherapeutics, Inc. (KR) | 2023-12-05 | — | — | US | disclosed |
| EP-4217358-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS OF USING SAME | 1st Biotherapeutics, Inc. (KR) | 2023-08-02 | — | — | EP | disclosed |
| US-11649255-B2 | Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same | 1ST Biotherapeutics, Inc. (KR) | 2023-05-16 | — | — | US | disclosed |
| CN-114599651-A | Indazoles as inhibitors of hematopoietic progenitor kinase 1(HPK1) and methods of use thereof | 第一生物治疗股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114599653-A | Indazoles as inhibitors of hematopoietic progenitor kinase 1(HPK1) and methods of use thereof | 第一生物治疗股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20220098193-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME | 1ST Biotherapeutics, Inc. | 2022-03-31 | — | — | US | disclosed |
| US-20220098219-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME | 1ST Biotherapeutics, Inc. | 2022-03-31 | — | — | US | disclosed |
| WO-2022064459-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS OF USING SAME | 1ST Biotherapeutics, Inc. (KR) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022064459-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS OF USING SAME | 1ST Biotherapeutics, Inc. (KR) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022064458-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS OF USING SAME | 1ST Biotherapeutics, Inc. (KR) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022064458-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS OF USING SAME | 1ST Biotherapeutics, Inc. (KR) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649255-B2 | Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same | IP6K1, HIPK1, IP6K3 | GAA 1829/4885YTHDC1 4554/4885CYP2C19 1320/4885 |
| US-20220098219-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME | IP6K1, HIPK1, IP6K3 | GAA 1829/4885YTHDC1 4554/4885CYP2C19 1320/4885 |
| US-20220098193-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME | IP6K1, HIPK1, IP6K3 | GAA 1829/4885YTHDC1 4554/4885CYP2C19 1320/4885 |
| US-11834467-B2 | Substituted indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors | IP6K1, MCL1, HIPK1 | GAA 2311/4885YTHDC1 4483/4885CYP2C19 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.